Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Duchemann

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Plos One|August 25, 2017
Identification of a discriminative metabolomic fingerprint of potential clinical relevance in saliva of patients with periodontitis using 1H nuclear magnetic resonance (NMR) spectroscopyMatthias Rzeznik, Mohamed Nawfal Triba, Pierre Levy, et al.
Translational Lung Cancer Research|July 23, 2021
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancerBoris Duchemann, Jordi Remon, Marie Naigeon, et al.
Psycho-Oncology|April 7, 2018
Assessing cognitive function in patients treated with immune checkpoint inhibitors: A feasibility studyStefania Cuzzubbo, Catherine Belin, Kader Chouahnia, et al.
Therapeutic Advances in Medical Oncology|February 6, 2023
Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world settingJean-Baptiste Assié, Christos Chouaïd, Hilario Nunes, et al.
Frontiers in Medicine|May 30, 2023
Differential diagnosis of pulmonary sarcoidosis: a reviewDominique Valeyre, Michel Brauner, Jean-François Bernaudin, et al.
Targeted Oncology|September 21, 2022
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French StudyAssya Akli, Nicolas Girard, Vincent Fallet, et al.
Cancers|May 16, 2023
Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-ImmunotherapyJulia Grambow-Velilla, Romain-David Seban, Kader Chouahnia, et al.
Annals of Nuclear Medicine|October 18, 2020
FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancerRomain-David Seban, Jean-Baptiste Assie, Etienne Giroux-Leprieur, et al.
Cancers|December 8, 2020
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung CancerBoris Duchemann, Jordi Remon, Marie Naigeon, et al.
Cancers|October 23, 2021
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and ChemotherapySamy Chelabi, Xavier Mignard, Karen Leroy, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Plos One|August 25, 2017
Identification of a discriminative metabolomic fingerprint of potential clinical relevance in saliva of patients with periodontitis using 1H nuclear magnetic resonance (NMR) spectroscopyMatthias Rzeznik, Mohamed Nawfal Triba, Pierre Levy, et al.
Translational Lung Cancer Research|July 23, 2021
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancerBoris Duchemann, Jordi Remon, Marie Naigeon, et al.
Psycho-Oncology|April 7, 2018
Assessing cognitive function in patients treated with immune checkpoint inhibitors: A feasibility studyStefania Cuzzubbo, Catherine Belin, Kader Chouahnia, et al.
Therapeutic Advances in Medical Oncology|February 6, 2023
Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world settingJean-Baptiste Assié, Christos Chouaïd, Hilario Nunes, et al.
Frontiers in Medicine|May 30, 2023
Differential diagnosis of pulmonary sarcoidosis: a reviewDominique Valeyre, Michel Brauner, Jean-François Bernaudin, et al.
Targeted Oncology|September 21, 2022
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French StudyAssya Akli, Nicolas Girard, Vincent Fallet, et al.
Cancers|May 16, 2023
Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-ImmunotherapyJulia Grambow-Velilla, Romain-David Seban, Kader Chouahnia, et al.
Annals of Nuclear Medicine|October 18, 2020
FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancerRomain-David Seban, Jean-Baptiste Assie, Etienne Giroux-Leprieur, et al.
Cancers|December 8, 2020
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung CancerBoris Duchemann, Jordi Remon, Marie Naigeon, et al.
Cancers|October 23, 2021
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and ChemotherapySamy Chelabi, Xavier Mignard, Karen Leroy, et al.
Pageof 9